The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,352.00
Bid: 12,350.00
Ask: 12,354.00
Change: 88.00 (0.72%)
Spread: 4.00 (0.032%)
Open: 12,268.00
High: 12,388.00
Low: 12,256.00
Prev. Close: 12,264.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-SAP drags down German shares, COVID-19 worries weigh on broader Europe

Mon, 26th Oct 2020 09:43

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* German DAX closes at lowest in almost 4 months

* SAP cutting its 2020 outlook, posts worst fall in 24 years

* SAP's pessimism dents hopes of global recovery - analyst

* Oil drop pressures energy stocks
(Updates to close)

By Sruthi Shankar and Susan Mathew

Oct 26 (Reuters) - German shares closed at their lowest in
nearly four months on Monday as Europe's most valuable tech
firm, SAP, experienced its worst trading day in 24
years after cutting its 2020 outlook.

The German DAX fell 3.7% as SAP slumped
almost 22% after abandoning medium-term profitability targets
and cautioning that its business would take longer than expected
to recover from the pandemic hit.

"SAP's pessimism does not bode well for hopes for the global
economic recovery to continue," said Edward Moya, senior market
analyst at OANDA, New York.

"If tech goes, the deteriorating outlook due to virus spread
will likely yield massive risk aversion as investors head for
the sidelines instead of rotating into cyclicals."

The wider European tech index slid 7.4%.

SAP's results came as a blip in the third-quarter earnings
season, which has been largely better than feared.

Meanwhile, fresh COVID-19-induced restrictions in Italy and
Spain to curb a resurgence in cases weighed on the rest of
Europe, with the pan-European STOXX 600 index closing
at a one-month low, down 1.8%.

Europe on Saturday became the second region after Latin
America to surpass 250,000 deaths, according to a Reuters tally.

The euro zone blue-chip index fell nearly 3%,
while Europe's travel and leisure sector, worst hit by the
movement curbs, was down 3.3%.

Nick Nelson, head of European equity strategy at UBS, said
the Swiss bank's target for STOXX 600 into the year-end is 340
points, about 4.5% below the current level, in part due to the
impact of the latest round of restrictions.

Surveys of euro zone purchasing managers last week showed
economic activity slipped back into decline in October,
heightening expectations for a double-dip recession as a second
wave of virus sweeps across the continent.

Globally, risk appetite was sapped by worries over slow
progress on a new U.S. stimulus bill and a looming presidential
election.

Milan's blue-chip index fell 1.8% even as ratings
agency Standard and Poor's upgraded Italy's sovereign outlook to
stable from negative.

Oil majors Total and Royal Dutch Shell
fell over 2.8% as crude prices slumped more than 3% on demand
worries.

Healthcare stocks remained supportive, with
AstraZeneca gaining 1.7% after it resumed the U.S. trial
of its experimental COVID-19 vaccine.

French stocks dipped 1.9%. Turkish leader Tayyip
Erdogan asked his compatriots to stop buying French goods on
Monday in the latest expression of anger in the Muslim world
over images being displayed in France of the Prophet Mohammad,
which some Muslims consider blasphemous.
(Reporting by Sruthi Shankar in Bengaluru; Editing by Sriraj
Kalluvila and Emelia Sithole-Matarise)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.